Prostaglandins: a new approach to glaucoma management with a new, intriguing side effect (Q41472756)

1 October 2017

1 reference

title

Prostaglandins: a new approach to glaucoma management with a new, intriguing side effect (English)

1 reference

1 October 2017

Bito LZ

1

1 reference

1 October 2017

1 February 1997

1 reference

1 October 2017

Survey of Ophthalmology

1 reference

1 October 2017

41 Suppl 2

1 reference

1 October 2017

S1-14

1 reference

Uveoscleral drainage of aqueous humour in human eyes

1 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2897%2980002-1

7 January 2021

Species differences in the responses of the eye to irritation and trauma: a hypothesis of divergence in ocular defense mechanisms, and the choice of experimental animals for eye research

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2897%2980002-1

7 January 2021

Prostaglandins. Old concepts and new perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2897%2980002-1

7 January 2021

Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2897%2980002-1

7 January 2021

Photochemical and photophysical studies on human lens constituents

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2897%2980002-1

7 January 2021

Bowman Lecture. Glaucoma--changing concepts

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2897%2980002-1

7 January 2021

Prostaglandin and non-prostaglandin mediated breakdown of the blood-aqueous barrier

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2897%2980002-1

7 January 2021

The effects of prostaglandin F2 alpha in the human eye

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2897%2980002-1

7 January 2021

Reduced intraocular pressure and increased ocular perfusion pressure in normal tension glaucoma: a review of short-term studies with three dose regimens of latanoprost treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2897%2980002-1

7 January 2021

Decreasing stromal iris pigmentation as a risk factor for age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2897%2980002-1

7 January 2021

The color of the human eye: a review of morphologic correlates and of some conditions that affect iridial pigmentation

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2897%2980002-1

7 January 2021

Prostaglandin action on ciliary smooth muscle extracellular matrix metabolism: implications for uveoscleral outflow.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2897%2980002-1

7 January 2021

Morphological study of the anterior segment of cynomolgus monkey eyes following treatment with prostaglandin F2 alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2897%2980002-1

7 January 2021

Cyclooxygenase-2 inhibitors: a new approach to the therapy of ocular inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2897%2980002-1

7 January 2021

Changes in eye colour during early childhood: sex and genetic differences

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2897%2980002-1

7 January 2021

Circadian intraocular pressure management with latanoprost: diurnal and nocturnal intraocular pressure reduction and increased uveoscleral outflow.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2897%2980002-1

7 January 2021

Aspirin prevents the disruption of the blood-aqueous barrier in the rabbit eye.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2897%2980002-1

7 January 2021

Around-the-clock intraocular pressure reduction with once-daily application of latanoprost by itself or in combination with timolol.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2897%2980002-1

7 January 2021

The prostaglandin transporter is widely expressed in ocular tissues.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2897%2980002-1

7 January 2021

Prostaglandin-induced iridial pigmentation in primates

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2897%2980002-1

7 January 2021

Oxidative stress-induced cataract: mechanism of action.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2897%2980002-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2897%2980002-1

7 January 2021

The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2897%2980002-1

7 January 2021

The molecular biology and ocular distribution of prostanoid receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2897%2980002-1

7 January 2021

Marked differential effects of prostanoid metabolites on rabbit intraocular pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2897%2980002-1

7 January 2021

Clinical evaluation of UF-021 (Rescula; isopropyl unoprostone).

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2897%2980002-1

7 January 2021

10.1016/S0039-6257(97)80002-1

Identifiers

DOI

0 references

PubMed ID

9154271

1 reference

PubMed ID

9154271